de Sá Moreira E, Robinson D, Hawthorne S, et al. - Analyzing patterns of care and treatment results for non-metastatic prostate cancer (nmPCA) in the United States of America (USA) in 2018, a great concordance was observed between the most current versions of PCa treatment recommendations and real-world data treatment patterns reported by US physicians, despite the fact that PCa treatment recommendations are rapidly changing due to advances in treatment.

• In a nationwide survey (CancerMPact) of physicians dealing with nmPCA patients, responses were obtained from 94 physicians with an average of 17.5 years of clinical practice, who had treated a combined average of 4,415 patients with nmPCA per month in 2018.

• About 40% of patients in stage I received either active surveillance or observation/no therapy, reducing to 20%, 8% and 6% in stages II, III and IV(M0), respectively.

• Relative to other radiotherapy modalities, intensity-modulated radiotherapy was favored, with rates of use ranging between 60% and 69% based on disease stage.

• For non-metastatic hormone-sensitive PCa cases with the first or second recurrence, the most common systemic treatment choices included leuprolide as monotherapy or in combination with enzalutamide, abiraterone or bicalutamide.

• Within 5 years of initial therapy for non-metastatic castration-resistant PCa, no relapse occurred in only 16.5% of non-metastatic castration-resistant PCa patients.